PDF(Pubmed)
Abstract：
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a heterogeneous disorder with elusive causes, but most likely because of clinical and other biological factors. As a vital environmental factor, the gut microbiome is increasingly emphasized in various refractory diseases including ME/CFS. The present study is aimed to enhance our understanding of the relationship between the gut microbiome and ME/CFS through data analysis of various clinical studies. We conducted a literature search in four databases (PubMed, Cochrane Library, Web of Science, and Google Scholar) until May 31, 2023. Our analysis encompassed 11 clinical studies with 553 ME/CFS patients and 480 healthy controls. A comparative analysis of meta data revealed a significant decrease in α-diversity and a noticeable change in β-diversity in the gut microbiome of ME/CFS patients compared to healthy controls. The notable ratio of Firmicutes and Bacteroides was 2.3 times decreased, and also, there was a significant reduction in the production of microbial metabolites such as acetate, butyrate, isobutyrate, and some amino acids (alanine, serine, and hypoxanthine) observed in ME/CFS patients. The lack of comparison under similar conditions with various standardized analytical methods has impeded the optimal calculation of results in ME/CFS patients and healthy controls. This review provides a comprehensive overview of the recent advancements in understanding the role of the gut microbiome in ME/CFS patients. Additionally, we have also discussed the potentials of using microbiome-related interventions and associated challenges to alleviate ME/CFS.
摘要：
肌痛性脑脊髓炎/慢性疲劳综合征（ME/CFS）是一种病因不明的异质性疾病，但很可能是由于临床和其他生物学因素。作为一个重要的环境因素，在包括ME/CFS在内的各种难治性疾病中，肠道微生物组日益受到重视。本研究旨在通过对各种临床研究的数据分析，增强我们对肠道微生物组和ME/CFS之间关系的理解。我们在四个数据库(PubMed，科克伦图书馆,WebofScience,和谷歌学者)，直到2023年5月31日。我们的分析包括11项临床研究，包括553例ME/CFS患者和480例健康对照。元数据的比较分析显示，与健康对照组相比，ME/CFS患者的肠道微生物组α多样性显着降低，β多样性显着变化。Firmicutes和拟杆菌属的显着比率降低了2.3倍，而且,微生物代谢物如乙酸盐的产生显着减少，丁酸盐,异丁酸,和一些氨基酸（丙氨酸，丝氨酸,和次黄嘌呤）在ME/CFS患者中观察到。在相似条件下缺乏与各种标准化分析方法的比较，阻碍了ME/CFS患者和健康对照的最佳计算结果。这篇综述全面概述了在了解肠道微生物组在ME/CFS患者中的作用方面的最新进展。此外,我们还讨论了使用微生物组相关干预措施和相关挑战来缓解ME/CFS的潜力.
